Recalls / Class II
Class IID-1307-2022
Product
Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724, Carton NDC# 0641-6044-25, Vial NDC# 0641-6044-01
- Brand name
- Lorazepam
- Generic name
- Lorazepam
- Active ingredient
- Lorazepam
- Route
- Intramuscular, Intravenous
- NDCs
- 0641-6044, 0641-6046, 0641-6045, 0641-6047
- FDA application
- NDA018140
- Affected lot / code info
- Lot # 060064, Exp. 06/2023, 070084, Exp. 07/2023, 070126, Exp. 07/2023, 080091, Exp. 08/2023, 080060, Exp. 08/2023
Why it was recalled
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Recalling firm
- Firm
- Hikma Pharmaceuticals USA Inc.
- Notification channel
- Letter
- Type
- Voluntary: Firm initiated
- Address
- 2 Esterbrook Ln, Cherry Hill, New Jersey 08003-4002
Distribution
- Quantity
- 4,739,000 vials
- Distribution pattern
- Nationwide in the USA
Timeline
- Recall initiated
- 2022-07-11
- FDA classified
- 2022-08-05
- Posted by FDA
- 2022-08-17
- Terminated
- 2023-09-14
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-1307-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.